2017
DOI: 10.1186/s13027-017-0124-y
|View full text |Cite
|
Sign up to set email alerts
|

An update on the management of breast cancer in Africa

Abstract: BackgroundThere is limited information about the challenges of cancer management and attempts at improving outcomes in Africa. Even though South and North Africa are better resourceds to tackle the burden of breast cancer, similar poor prognostic factors are common to all countries. The five-year overall Survival rate for breast cancer patients does not exceed 60% for any low and middle-income country (LMIC) in Africa. In spite of the gains achieved over the past decade, certain characteristics remain the same… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
144
1

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 134 publications
(151 citation statements)
references
References 106 publications
6
144
1
Order By: Relevance
“…[2,6] In Rwanda, Pace and colleagues recently discovered that the median delay to treatment was 15 months and delays of ≥6 months were significantly associated with more advanced-stage cancer. [6] Over the past two decades, several older studies documented an early-age onset of breast cancer in Africa, [7] which provides support for recent findings in Rwanda indicating the median age of 49 years at time of diagnosis. [6] In the US, the median age is 62 years and less than five percent are diagnosed younger than 40 years of age.…”
Section: Introductionmentioning
confidence: 56%
“…[2,6] In Rwanda, Pace and colleagues recently discovered that the median delay to treatment was 15 months and delays of ≥6 months were significantly associated with more advanced-stage cancer. [6] Over the past two decades, several older studies documented an early-age onset of breast cancer in Africa, [7] which provides support for recent findings in Rwanda indicating the median age of 49 years at time of diagnosis. [6] In the US, the median age is 62 years and less than five percent are diagnosed younger than 40 years of age.…”
Section: Introductionmentioning
confidence: 56%
“…There is often extreme burden leading to delayed treatment. Moreover, frequent interruption of radiotherapy treatments due to the costs of traveling for therapy can be significant (30,31). Progressive introduction of shortened radiotherapy regimens like the one proposed in this study may effectively contribute to improved compliance and access to adjuvant breast cancer radiotherapy in areas with limited radiotherapy facilities.…”
Section: Discussionmentioning
confidence: 96%
“…The lack of reliable hormone receptor status assessment in LMICs hampers the optimal selection of endocrine interventions, and this results in a significant proportion of patients receiving chemotherapy instead of lower toxicity (and potentially more effective) endocrine therapy. Given that more than half of African breast cancers are hormone receptor positive and given the relative ease of administering oral therapies in comparison with other systemic treatments, the role of endocrine therapy and hormone receptor testing warrants careful examination in all resource settings 34 . Thus, one priority in the implementation of systemic therapy is represented by reliable tumor marker assessment to correctly determine the biology of the disease (primarily estrogen receptor and HER2) to allow appropriate selection of patients for endocrine therapy versus chemotherapy treatment as well as HER2 therapies when available.…”
Section: Multimodality Breast Cancer Treatment In Lmicsmentioning
confidence: 99%